Despite this numerical difference, maximum FP exposure was generally low, indicating an overall very limited systemic FP bioavailability for all investigational treatments
Objectives: To compare the systemic bioavailability (assessed by cortisol suppression) of high-dose budesonide when given by four inhaler devices and orally
High first-pass metabolism and consequently negligible oral bioavailability are found for FF, fluticasone propionate (FP), mometasone furoate (MF) and
The exhalation delivery system with fluticasone propionate (Xhance®) has been shown to deliver drug substantially more broadly in the nasal cavity (particularly into superior/posterior regions), with less off
This unusual result, however, was based
one of the lowest systemic exposures and potential risks among INCS used for AR [3, 8]
Prior to the present study, the intranasal bioavailability of FP had not been accurately measured, due to assay
After intranasal administration, the systemic bioavailability of azelastine HCl is approximately 40%